Publication:
Pulmonary delivery offavipiravir in rats reaches high local concentrations without causing oxidative lung Injury or systemic side effects

Simple item page
dc.contributor.authorDURMUŞOĞLU, LÜTFİYE
dc.contributor.authorYEGEN, BERRAK
dc.contributor.authorsAkbal-Dagistan O., Sevim M., Sen L. S. , Basarir N. S. , Culha M., Erturk A., Fael H., Kaptan E., Sancar S., DURMUŞOĞLU L., et al.
dc.date.accessioned2022-12-02T12:59:33Z
dc.date.available2022-12-02T12:59:33Z
dc.date.issued2022-11-01
dc.description.abstractFavipiravir displays a rapid viral clearance, a high recovery rate and broad therapeutic safety; however, its oral administration was associated with systemic side effects in susceptible patients. Considering that the pulmonary route could provide a high drug concentration, and a safer application with less absorption into systemic circulation, it was aimed to elucidate whether favipiravir delivered via soft-mist inhaler has any deleterious effects on lung, liver and kidney tissues of healthy rats. Wistar albino rats of both sexes (n = 72) were placed in restrainers, and were given either saline or favipiravir (1, 2.5, 5 or 10 mg/kg in 1 mL saline) by inhalation within 2 min for 5 consecutive days. On the 6th day, electrocardiographic recording was obtained, and cardiac blood and lung tissues were collected. Favipiravir did not alter cardiac rhythm, blood cell counts, serum levels of alanine transaminase, aspartate transaminase, blood urea nitrogen, creatinine, urea or uric acid, and did not cause any significant changes in the pulmonary malondialdehyde, myeloperoxidase activity or antioxidant glutathione levels. Our data revealed that pulmonary use of favipiravir via soft-mist inhaler enables a high local concentration compared to plasma without oxidative lung injury or cardiac or hepatorenal dysfunction.
dc.identifier.citationAkbal-Dagistan O., Sevim M., Sen L. S. , Basarir N. S. , Culha M., Erturk A., Fael H., Kaptan E., Sancar S., DURMUŞOĞLU L., et al., "Pulmonary Delivery of Favipiravir in Rats Reaches High Local Concentrations without Causing Oxidative Lung Injury or Systemic Side Effects", PHARMACEUTICS, cilt.14, sa.11, 2022
dc.identifier.doi10.3390/pharmaceutics14112375
dc.identifier.endpage15
dc.identifier.issn1999-4923
dc.identifier.issue11
dc.identifier.startpage1
dc.identifier.urihttps://avesis.marmara.edu.tr/api/publication/8d0e1164-12ef-4f58-a273-2f2fe4b5dd36/file
dc.identifier.urihttps://hdl.handle.net/11424/283505
dc.identifier.volume14
dc.language.isoeng
dc.relation.ispartofPHARMACEUTICS
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTemel Eczacılık Bilimleri
dc.subjectEczacılık
dc.subjectYaşam Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTemel Bilimler
dc.subjectBasic Pharmaceutics Sciences
dc.subjectPharmacology and Therapeutics
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectNatural Sciences
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectPHARMACOLOGY & PHARMACY
dc.subjectPHARMACOLOGY & TOXICOLOGY
dc.subjectLife Sciences (LIFE)
dc.subjectFarmakoloji
dc.subjectFarmakoloji, Toksikoloji ve Eczacılık (çeşitli)
dc.subjectGenel Farmakoloji, Toksikoloji ve Eczacılık
dc.subjectFarmakoloji (tıbbi)
dc.subjectİlaç Rehberleri
dc.subjectPharmacy
dc.subjectPharmacology
dc.subjectPharmacology, Toxicology and Pharmaceutics (miscellaneous)
dc.subjectGeneral Pharmacology, Toxicology and Pharmaceutics
dc.subjectPharmacology (medical)
dc.subjectDrug Guides
dc.subjectfavipiravir
dc.subjectantiviral
dc.subjectCOVID-19
dc.subjectinhalation
dc.subjectpulmonary route
dc.subjectoxidative lung injury
dc.subjecthepatotoxicity
dc.subjectrenal toxicity
dc.subjectcardiac toxicity
dc.subjectSOFT MIST(TM) INHALER
dc.subjectFEVER VIRUS-INFECTION
dc.subjectAEROSOL
dc.subjectT-705
dc.subjectINHIBITOR
dc.subjectTRANSMISSION
dc.subjectCORONAVIRUS
dc.subjectDEPOSITION
dc.subjectINTERVAL
dc.subjectHEALTHY
dc.subjectfavipiravir
dc.subjectantiviral
dc.subjectCOVID-19
dc.subjectinhalation
dc.subjectpulmonary route
dc.subjectoxidative lung injury
dc.subjecthepatotoxicity
dc.subjectrenal toxicity
dc.subjectcardiac toxicity
dc.titlePulmonary delivery offavipiravir in rats reaches high local concentrations without causing oxidative lung Injury or systemic side effects
dc.typearticle
dspace.entity.typePublication
local.avesis.id8d0e1164-12ef-4f58-a273-2f2fe4b5dd36
local.indexed.atWOS
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublication05614eca-392c-4f70-a728-f6fec5586b16
relation.isAuthorOfPublicatione4eaf9ac-f8dc-4e2b-b940-895cc906790d
relation.isAuthorOfPublication.latestForDiscovery05614eca-392c-4f70-a728-f6fec5586b16

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
28.pdf
Size:
2.61 MB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs